Ruimin Hong

机构：Cell Technology (China), First Affiliated Hospital Zhejiang University, Zhejiang University

发表论文 76 篇 · 总被引 788 次 · h-index 13

代表论文

• CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells (2025 · Cell Reports Medicine · 被引 46)
• Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (2025 · JAMA Oncology · 被引 31)
• Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (2025 · Journal for ImmunoTherapy of Cancer · 被引 17)
• Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies (2024 · Experimental Hematology and Oncology · 被引 13)
• Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia (2025 · Experimental Hematology and Oncology · 被引 9)
• OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). (2024 · Journal of Clinical Oncology · 被引 9)